Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
75,602,672
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
42,987,158
-
Shares change
-
+1,028,378
-
Total reported value, excl. options
-
$3,611,907,936
-
Value change
-
+$90,022,119
-
Put/Call ratio
-
15.3%
-
Number of buys
-
86
-
Number of sells
-
-45
-
Price
-
$84.06
Significant Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q4 2021
157 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q4 2021.
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42,987,158 shares
of 75,602,672 outstanding shares and own 56.86% of the company stock.
Largest 10 shareholders include FMR LLC (6,795,831 shares), PRICE T ROWE ASSOCIATES INC /MD/ (4,382,881 shares), Matrix Capital Management Company, LP (4,349,279 shares), VANGUARD GROUP INC (3,186,986 shares), BlackRock Inc. (2,842,945 shares), Avidity Partners Management LP (2,715,000 shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2,628,409 shares), VIKING GLOBAL INVESTORS LP (2,118,284 shares), STATE STREET CORP (1,346,416 shares), and PRIMECAP MANAGEMENT CO/CA/ (1,253,640 shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.